Research Coordinator Alternate Name Pharmacy Supplies Description A multicenter, single arm, non-blinded safety and dose TMC-CLV-07- Rebecca Violette: 662-2066, Accelerate Clevidipine in 100ml Type II clear glass titration study evaluating the ability of clevidipine to rapidly Clevidipine pager: 741-3257, fax: 662- control elevated blood pressure in the setting of and acute intracerebral hemorrhage (ICH) 6326.The Medicines Company Acyclovir in Neonatal Carol McCarthy, MD 662- Zovirax™ Two studies using acyclovir to suppress herpes after Acyclovir Acyclovir or placebo 5522; Pager 767-6781 Herpes Suppression treatment for CNS infections or skin-eye-mouth infection Biologic lung volume reduction by obstructing selected upper AERIS 01-C07-001 207-662-4519 Hydrogel Hydrogel for bronchoscopy lobe areas with hydrogel. Done under bronchoscopy for AERIS Therapeutics emphysema, etc Boceprevir & PEG2b/Ribavirin for the treatment of Chronic Erythropoietin, Anemia P06086 Erythropoietin, Ribavirin, Hepatitis C in Treatment-Naïve Subjects:A Comparison of Sue Mortenson,396-8078, fax Ribavirin, PEG2b,Boceprevir Erythropoietin Use VS. Ribavirin Dose Reduction for the 885-8391, pager 741-0597 PEG2b,Boceprevir Management of Anemia.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-
GS-US-300-
Center, Parallel-Group Study to Evaluate the Efficacy and Safety
ARTEMIS-PH Ambrisentan, 662-4519, fax 761-3022, Ambrisentan/Placebo
of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis
Letairis pager 741-7234 Determine if the initial adjunctive use of Pharmacomechanical Activase Catheter-Directed Thrombolysis (PCDT) in symptomatic Renee Daigle, MA phone 883- (Recombinant Tissue Activase patients with acute proximal deep vein thrombosis reduces the 5295, pager N/A Plasminogen occurrence of the Post-Thrombotic Syndrome over 24 months NIH Activator, rt-PA) follow-up. Randomized, Placebo-Controlled Comparison of the Effects of AWARD H9X-MC-GBDA LY2189265 and LY2189265, Exenatide, Metformin, and Two Doses of LY2189265 or Exenatide on Glycemic Control in Judy DeMena, 396-8062, fax Exenatide pioglitatonze Patients with Type 2 Diabetes on Stable Doses of Metformin 885-8391 and Pioglitazone Joanne Burgess 0678 767- Vascular endothelial growth factor is placed in an adenovirus AWARE Cardium® Drug to cath lab. Stored in ultra cold and injected through cardiac cath to promote collateral Cardium Therapeutics circulation in coronary artery disease Cyclosporin oral vs 2 regimens of Krista Garrison Office 7191 Belatacept Belatacept injections during transplant Belatacept vs Cyclosporin for immunosuppression in renal Page 741-1409 and as outpatient every 4 weeks x 1 transplant (BRISTOL-MYERS SQUIBB) Robin Donovan 883-0069 Bevacizumab GOG Bevacizumab every 3 weeks x 5 cycles Bevacizumab, an antiangiogenesis drug in combination with Fax 8837972 (NCI- Avastin™ or x22 cycles vs placebo conventional therapy for late stage ovarian cancer GYNECOLOGIC ONCOLOGY GROUP) A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8g/day) Asacol® Mesalamine/placebo tablets in numbered Tim Messitt, phone: 662- Mesalamine 400mg Delayed-released Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of 6712, fax: 662-5528 Remission of Ulcerative Colitis. A Randomized, Multi-Center, Double-Blind, Parallel, 28431754 Judy DeMena, 396-8062, fax Canagliflozin Canagliflozin Placebo-Controlled Study of The Effects of JNJ-28431754 (Canagliflozin) on Cardiovascular Outcomes in Adult Subjects With Type 2 885-8391 Diabetes Mellitus CCS Mike Butts775-3600 Me Childrens Cancer Pgm COG P9962 NSC 609699 Intrathecal injection Phase II trial in patients with refractory meningeal Topotecan Kathleen Glick 8857565 (Critical Care Systems) malignancies (CHILDRENS ONCOLOGY GROUP) CCS Mike Butts775-3600 Me Childrens Cancer PGM Injection Irinotecan Phase II trial for refractory solid tumors Kathleen Glick 8857565 (Critical Care Systems) (CHILDRENS ONCOLOGY GROUP) B-Cell depletion by anti-CD20 (Rituximab) in renal allograft CTOT-02 Rituximab recipients who develop de novo anti-HLA alloantibodies will Krista Garrison 662-7191, fax Rituximab Rituximab vials result in inhibition of alloantibody production and attenuation 662-7160, pager 741-1409 of chronic humoral rejection (CTOT-02) A Phase II single arm study of carboplatin and Doxil plus DOXIL DOXILOVC2007 Carboplatin,Doxil, Patricia Shorthill 662-5719, Stored and dispensed at Scarborough bevacizumab in subjects with platinum sensitive recurrent Bevacizumab pager 741-0308 ovarian, fallopian tube and primary peritoneal cancers Protocol desvenlafaxine Titration Kits, Treatment bottles, and A double-blind, placebo-controlled study assessing the safety Judy DeMena,phone662- 3151A2-3353- cuccinate sustained Taper packages of DVS-SR. All stored and efficacy of DVS-SR for the treatment of vasomotor 8310,pager 741-1993 release tablets or in vault. symptoms associated with menopause. CCS Mike Butts775-3600 Erwinase™ Erwinia L Subcutaneous injection supplied from Me Childrens Cancer Pgm For pediatric ALL patients allergic to E Coli Asparaginase Asparaginase Critical Care Systems Kathleen Glick 8857565 (Fisher Bioservices) Alteplase To determine the optimal strategy in the prevention and Jane Kane,RN, phone:662- (Braxton, Alteplase (limited supply to be stored in elimination of intraluminal saphenous vein graft clot in patients Activase®, alteplase 6991,fax: 662-2894, pager: undergoing Endoscopic saphenous vein harvesting for coronary Kramer,MD) 741-6453 artery bypass grafting.
A 16-Week, International, Multi-center, Double-Blind,
TDE-PH-308 Treprostinil
Randomized, Placebo-Controlled Study of the Efficacy and
Treprostinil diethanolamine/ 662-4519, pager: 741-7234, diethanolamine/
Safety of Oral UT-15C Sustained Release Tablets in Subjects
Remodulinn Placeboo fax: 741-30222 Placeboo PEG,PVP, Na Gelclair® is a proprietary oral protectant that adheres to and Hyapuronate, protects mucosal surfaces damaged by radiation for head and Kits with active drug or sodium Donna Green and Cyndi O'Brien Bioadherent Hydroxyehtyl- neck cancer. Patients are randomized to Gelclair™ or Gelclair® cellulose, bicarbonate standard treatment [email protected], 6776 standard therapy which is sodium bicarbonate rinse. Glycyrrhetinic together with supplies such as fax:6770 Evaluating staff are blinded as kits are shipped directly from acid, vs. toothbrush, mouthwash, etc pharmacy to patient’s home and patient5 is contacted by a separate unblended third party. GOG-0129Q Gemcitabine
A Phase II evaluation of Gemcitabine in the treatment of
recurrent or persistant endometrial carcinoma.
Mifeprostone is a progestin receptor antagonist which inhibits Oral tablets are stored and dispensed Mifepristone growth of ovarian epithelial cells. Patients will receive 200mg by the research nurse in the Gynecologic Robin Donovan 883-0069 orally daily to estimate anti-tumor response in persistent or oncology practice off site in Fax 8837972 (NCI-GOG) Mifeprex™ recurrent epithelial ovarian, fallopian or primary peritoneal Scarborough carcinoma. Original use is as an abortifacent Doxorubicin Doxorubicin-Cisplatin-Paclitaxel vs Compare the two regimens in Stage III & IV recurrent Robin Donovan 883-0069 Cisplatin Paclitaxel Carboplatin-Paclitaxel every 21 days endometrial cancer to determine if the two drug is as Fax 8837972 (NCI-GOG) Carboplatin times 7 cycles effective and less toxic than the 3 drug regimen Robin Donovan 883-0069 Bevacizumab Bevacizumab every 3 weeks x 5 cycles Bevacizumab, an antiangiogenesis drug in combination with Avastin™ Fax 8837972 (NCI-GOG) or x22 cycles vs. placebo conventional therapy for late stage ovarian cancer In cervical carcinoma limited to the pelvis, tirapazamine will Tirapazamine injection along with be given with cisplatin along with radiotherapy. Tirapazamine Robin Donovan 883-0069 Tirapazamine cisplatin to outpatients in the is a hypoxia selective anti-tumor agent thought to enhance Fax 8837972 (NCI-GOG) Scarborough infusion room cisplatin anti-tumor efficacy A PHASE II EVALUATION OF PACLITAXEL, CARBOPLATIN, AND BSI-201 IN THE TREATMENT OF ADVANCED, BIPAR#20070102 PERSISTENT, OR RECURRENT UTERINE CACINOSARCOMA Fax 8837972 AZD6244 is supplied as 50 or 100mg A Phase II Trial of AZD6244 (NSC #741078, IND #77782) powder vials in boxes containing 16 vials. In Women With Recurrent Low-Grade Serous Carcinoma Of Captisol is supplied in boxes containing The Ovary. 16 blow fill seals(BFS)/box. A Prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual Anti-platelet therapy (DAPT) in subjects undergoing HCRI-DAPT DAPT, Clopidogrel, Prasugrel, Placebo Percutaneous coronary intervention (PCI) with either drug- Jeannie Gallant, 662-3408, fax 662-6315 eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions. A Phase 3, Randomized, Double-Blind, Cross-Over, Active- Buphenyl (sodium phenylbutyrate, Controlled Study of the Efficacy and Safety of HPN-100, Sue Mortensen, phone: (207) HPN-100-006 phenylbutyric acid. NaPBA,4-phenylbutyric acid, HPN-100, Glyceryl tri-(4-phenylbutrate), for the Treatment of Adults 396-8078, fax: 885-8391, pager with Urea Cycle Disorders 741-0597 To determine the safety and tolerability of inhaled hypertonic In-House study: Hyper-Saline Hyper-Sal 7% Hypertonic Saline From Vault, vials of 7% hypertonic saline (HTS) in patients with cystic fibrosis CF) and forced Dr. Zuckerman and Dr. Mahesh expiratory volume in one second (FEV1)less than 40% of predicted.
A Multicenter, Randomized. Double-Blind, Double-Dummy,
Judy DeMena,phone 662- Lutrepatch/Placebo Lutrepatch/Placebo kits, bottles of 5
Placebo-Controlled Study to Assess the Efficacy and Safety of Three
LUTREPATCH GnRH 8310,pager 741-1993 tablets of Medroxyprogesterone. All
Dosage Strengths of Pulsatile GnRH Delivered from an
Medroxyprogesterone meds are in vault.
Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment with Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory
Safety & efficacy of long term mannitol inhalation in cystic Rhoda Kennedy-DuDevoir 207- MANNITOL DPM-CF-302 Outpatient prescriptions of mannitol for fibrosis. Inhalation may improve mucociliary clearance as an 662-6550 Pager 741-7234 Mannitol inhalation inhalation osmotic agent increasing hydration or change viscoelastic Fax 207-761-3022 properties of mucous PHARMAXIS Capsules prepared by pharmacy with MISOPROSTIL Elizabeth Linell 662-6219 fax Misoprostil active misoprostil or placebo supplied in Use to dilate neck of cervix before endometrial biopsy. 662-2702 MMC OB/Gyn clinic kits to OB-Gyn clinic Early access study in patients who have failed on other Raltagravir™ Oral tablets to outpatients along with regimens. MK-0518 is an antiretroviral HIV-1 integrase Sandra Putnam 2995 page L-000900612 inhibitor. It inhibits the insertion of HIV-1 DNA into host 7676655 MERCK A study to do a prospective, randomized trial to determine whether prophylactic ascorbic acid alone, ascorbic acid with How to drive Jane Kane, RN, phone:662- Ascorbic Acid 500mg chewable tablets amiodarone, or amiodarone alone, when given along with beta Ascorbic Acid 6991, fax: 662-2894, pager: Clay nuts! and amiodarone 200mg oral tablets blockers will decrease the incidence of postoperative AF in 741-6453 adult cardiac surgery in all comers as compared with beta blockers alone. Claire Berg, Joanne Burgess, A prospective, randomized, multicenter trial to assess an and fJeannie Gallant Platinum S2046 Plavix, clopidogrel Plavix, #180 or Ticlid #360 Everolimus-Eluting stent system for the treatment of up to phone:662-4897, pager:767- and Ticlid, ticlopidine two De Novo coronary artery lesions. 6785 Boston Scientific Corporation
Planned Transition to Sirolimus-based Therapy versus Tacrolimus Krista Garrison phone: 662- Planned Transition 0468E8-4500 Rapamune, Sirolimus Rapamune, Sirolimus 7191, fax: 662-7160, pager: 741-1409 A phase 1-2, multi-center, dose escalation study of a single Krista Garrison phone: 662- Proteon PRT-201-101 dose of PRT-201 administered immediately after PRT-201/pl;acebo 7191, pager 741-1409 Arteriovenous fistula creation in patients with chronic kidney Proteon Therapeutics disease. Tracy Robbins& Laurel Libby Quetiapine Seroquel™ 50mg tablets and matching placebo to Safety and efficacy of Quetiapine in treatment of ICU 2066 741-3257 quetiapine inpatients in varying doses every 12 hrs delirium (INTERNAL) Ramipril has an unexplained protective effect on kidneys independent of blood pressure lowering. This study tests the RAPAMUNE Krista Garrison Office 7191 Prescriptions dispensed from MMC efficacy of Ramipril in preventing a urinary protein to Ramipril and sirolimus Page 741-1409 0468E5-4439 pharmacy creatinine ratio (U p/c) greater than 0.5 following conversion WYETH to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients Open label extension study of the long term safety of Rhoda Kennedy-Dudevoir 662- RECAP PIPF-012 Rx through Out Patient pharmacy. Pirfenidone, Placebo Pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) 6550,page 741-7234.Tina Bottles of #180 who complete the CAPACITY Study. Manly 662-4519 Jane Kane, RN, phone:662- RED-CABG Acadesine Acadesine diluted in IV bag, cardioplegia Reduction in Cardiovascular Events By AcaDesine in Acadesine 6991, fax: 662-2894, pager: solution Patients Undergoing CABG 741-6453 ACT-064992, Seraphin (ACT-064992) 3mg, 10mg, or To demonstrate that either dose of ACT-064992 prolongs the Tina Manley & Rhoda Kennedy- SERAPHIN Seraphin placebo, in kits of 6 bottles, 36 time to the first morbidity or mortality event in patients with DuDevoir,phone 662-4519 AC-055-302 tabs/bottle symptomatic pulmonary arterial hypertension. Actelion A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE Patricia Shorthill, phone 883- SHH4489g GDC-0449 GDC-0449 or From vault, GDC-0449/Placebo EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE 0069, pager 741-0308 placebo (150mg) THERAPY IN PATIENTS WITH OVARIAN CANCER IN A Genentech SECOND OR THIRD COMPLETE REMISSION Study the efficacy and safety of Sorafenib compared to BAY 43-9006 Sorafenib/Placebo bottles, #140, Patricia Shorthill 741-0308 SORAFENIB Sorafenib placebo in ovarian epithelial cancer or primary peritoneal 200mg. Dispensed through Out-Patient Nexavar® (Nexavar®),Placebo cancer patients who have achieved a complete clinical response Pharmacy after standard platinum/taxane chemotherapy. B1321001 A phase 3, multi center, double-blind, placebo-controlled, Tina Manley phone: 662-4519, B1321002 Blister pack (32 day supply) of Thelin, Sitaxsentan safety and efficacy study of sitaxsentan sodium in subjects pager: 741-7234 sitaxsentan 100mg or placebo B1321003 with pulmonary arterial hypertension. BHR-100 (6% IV fat A Randomized, Double-Blind, Placebo Controlled Phase III Steven Desjardins 774-2381, Synapse BHR-100-301 emulsion containing BHR-100/Placebo Study to Investigate the Efficacy and Safety of Progesterone fax 774-0459, pager 741- 2.0mg/ml in Patients with Severe Traumatic Brain Injury progesterone Tim Messitt Maine Pediatric Studied in cystic fibrosis patients. PGY2 receptor agonist that Specialty Group 887 TIGER-2 Denufosol Outpatient prescriptions of inhalation causes chloride and liquid secretion in the airway and Congress St., Ste 320 Portland, Tetrasodium solution stimulates mucous production and ciliary action to restore or ME 04102 maintain mucociliary clearance Ph: 662.6712 Fax: 662.5527 [email protected] Tim Messitt Maine Pediatric Specialty Group 887 TIGER-OLE Denufosol Outpatient prescriptions of inhalation For patients who have completed TIGER-2 protocol. Study Congress St., Ste 320 Portland, Tetrasodium solution provides patients with an additional 48 weeks of medication . ME 04102 Ph: 662.6712 Fax: 662.5527 [email protected] A Phase 3, Open-Label Study of the Safety of HPN-100 for Sue Mortensen, phone: (207) TREAT-UCD HPN-100 HPN-100 the Long Term Treatment of 396-8078, fax: 885-8391, Urea Cycle Disorders pager 741-0597 Only available as investigational drug under “Expanded Physician requesting becomes VARIZIG VZIG Varicella Zoster Immune globulin for Varicella zoster Access Protocol” May be available for pediatric patients at principal investigator Immune Globulin exposure in immunocompromised patients Critical Care Systems. For adults will have to obtain from (CANGENE) sponsor under a tight timeline. A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- Tim Messitt Maine Pediatric VX-770/Placebo, 150mg oral blue film- CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE Specialty Group 887 VERTEX VX-770 coated tablets. Supplied in kits of 4 SAFETY AND EFFICACY OF VX-770 IN SUBJECTS AGED 12 Congress St., Ste 320 Portland, weekly child-resistant blister dosing YEARS AND OLDER WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION. Ph: 662.6712 Fax: 662.5527 [email protected] Voraxaze is ordered on a patient An Open Label Treatment Protocol For The Use Of Voraxaze VORAXAZE Kathleen Glick, phone: 885- Voraxaze specific need: it is not stocked. The As Adjunctive Treatment For Patients Experiencing Or At Risk 7565, fax: 885-7577 $10,000 vials are refrigerated. Of Methotrexate Toxicity A Prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual Antiplatelet therapy (DAPT) in subjects undergoing Numbered kits containing either: Jeannie Gallant, phone: 662- Clopidogrel, prasugrel clopidogrel, prasugrel, or placebo. Percutaneous coronary intervention (PCI) with either drug- 3408, fax: 662-6315 eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.
Anwendung LEV DESITIN® kann mahlzeitenunabhängigen mit oder ohne Nahrung eingenommen werden. Bei der empfohlenen Einnahme werden die LEV DESITIN®-Minitabletten direkt aus dem Beutel in den Mund eingenommen. Anschließend sollte mit ausreichend Flüssigkeit (z. B. einem Glas Wasser oder Fruchtsaft) Kompendium LEV DESITIN® Einnahmeempfehlung (Levetiracetam) 1.
Published Online First on April 14, 2008 as 10.1158/1940-6207.CAPR-08-0048 Impact of Economic, Regulatory, and Patent Policies on Innovationin Cancer ChemopreventionChemoprevention agents are an emerging new scientific area that holds out thepromise of delaying or avoiding a number of common cancers. These new agents facesignificant scientific, regulatory, and economic barriers, however, whic